Gamida Cell Ltd. (GMDA)

Gamida Cell Ltd. (GMDA) Healthcare & Pipeline Overview

Gamida Cell Ltd. is a clinical-stage biopharmaceutical company pioneering advanced cell therapies for blood cancers and serious hematologic diseases. Leveraging its proprietary platforms, the company is advancing lead candidate omidubicel through Phase III for hematologic malignancies, alongside a robust natural killer cell pipeline targeting various oncological indications.

What Is the Investment Thesis for GMDA?

Gamida Cell Ltd. presents a research focus centered on its advanced cell therapy pipeline, particularly omidubicel, which has completed Phase III clinical trials for high-risk hematologic malignancies. This late-stage asset represents a primary value driver, with potential regulatory approval and subsequent commercialization serving as significant upcoming catalysts. The company's strategy also encompasses the development of GDA-201, an NK cell-based immunotherapy in Phase I/II studies for non-Hodgkin lymphoma and multiple myeloma, alongside a broader NK cell pipeline, indicating a multi-pronged approach to addressing oncology and hematology markets. The company's financial profile, characterized by a negative profit margin of -3531.2% and a gross margin of -95.0%, reflects its clinical-stage status and substantial investment in research and development without significant product revenue. A beta of 1.03 suggests volatility aligned with the broader market, typical for a biotechnology firm. Future value creation is contingent upon successful clinical trial outcomes, favorable regulatory decisions, and the ability to effectively commercialize its lead candidates. The progression of omidubicel through regulatory review and the advancement of the NK cell pipeline are critical milestones for evaluating Gamida Cell's long-term potential.

Based on FMP financials and quantitative analysis

GMDA Key Highlights

• Market Capitalization: $0.00B, reflecting its early-stage development and current valuation.
• Profit Margin: -3531.2%, indicative of substantial investment in research and development without commercial product revenue.
• Gross Margin: -95.0%, further emphasizing the company's focus on R&D rather than product sales at this clinical stage.
• Beta: 1.03, suggesting the stock's volatility is closely aligned with the overall market.
• Dividend Yield: None, as is typical for clinical-stage biotechnology companies reinvesting all capital into pipeline development.

Who Are GMDA's Competitors?

GMDA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GMDA's Key Strengths?

• Advanced clinical pipeline with omidubicel having completed Phase III trials for high-risk hematologic malignancies.
• Diversified pipeline including NK cell-based immunotherapies (GDA-201) and earlier-stage candidates.
• Focus on high-unmet-need areas in blood cancers and serious hematologic diseases.
• Specialized expertise in cell therapy development and manufacturing.

What Are GMDA's Weaknesses?

• Significant negative profit margin (-3531.2%) and gross margin (-95.0%) due to clinical-stage status.
• No commercialized products or significant revenue streams currently.
• High reliance on successful clinical trial outcomes and regulatory approvals.
• Small market capitalization for a biotech company with late-stage assets.

What Could Drive GMDA Stock Higher?

• Potential regulatory approval decision for omidubicel in high-risk hematologic malignancies, following its completed Phase III clinical trials.
• Announcement of further clinical data or progression for GDA-201 in Phase I/II studies for non-Hodgkin lymphoma and multiple myeloma.
• Advancement of additional candidates within the natural killer (NK) cell pipeline (GDA-301, GDA-401, GDA-501, GDA-601) into later preclinical or early clinical stages.
• Initiation of new clinical trials or expansion of existing trials for omidubicel into additional indications, such as severe aplastic anemia.

What Are the Key Risks for GMDA?

• Financial-distress signal — its Altman Z-Score of -12.90 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Significant financial losses and negative profitability, as evidenced by a profit margin of -3531.2% and gross margin of -95.0%, reflecting substantial R&D expenditure without product revenue.
• Clinical trial failures or delays for omidubicel, GDA-201, or other pipeline candidates, which could jeopardize future commercialization and financial viability.
• Regulatory setbacks, including non-approval or delayed approval of omidubicel by health authorities, which would prevent market entry and revenue generation.
• Intense competition within the cell therapy and cancer immunotherapy markets from established pharmaceutical companies and other emerging biotechs.
• Challenges in securing sufficient capital to fund ongoing research, development, and potential commercialization efforts for its extensive pipeline.

What Are the Growth Opportunities for GMDA?

• Omidubicel Commercialization for Hematologic Malignancies: The successful regulatory approval and subsequent commercial launch of omidubicel for high-risk hematologic malignancies represent a primary growth driver. This cell therapy, having completed Phase III clinical trials, addresses a critical need for improved bone marrow transplantation outcomes. The market for allogeneic hematopoietic stem cell transplantation (HSCT) is substantial, with tens of thousands of procedures performed annually worldwide, and omidubicel aims to expand access and improve engraftment for patients lacking suitable donors or experiencing delays. A successful launch could establish Gamida Cell as a key player in the transplant medicine segment, potentially generating significant revenue streams within the next 1-3 years, contingent on regulatory timelines and market adoption.
• Expansion of Omidubicel into Severe Aplastic Anemia: Beyond its lead indication, omidubicel is also undergoing Phase I/II clinical trials for severe aplastic anemia. This represents an additional market opportunity, as severe aplastic anemia is a rare but life-threatening bone marrow failure disorder with limited treatment options. Demonstrating efficacy and safety in this indication could unlock a new patient population and revenue stream. The successful progression through these earlier-stage trials and potential future regulatory submissions could extend omidubicel's market reach, diversifying the company's product portfolio and reducing reliance on a single indication over a 3-5 year timeline.
• Advancement of GDA-201 for Lymphoma and Myeloma: The development of GDA-201, a natural killer (NK) cell-based cancer immunotherapy, for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma, offers significant growth potential. Both diseases represent large and challenging oncology markets with a continuous need for novel therapeutic approaches, especially for patients who have failed prior treatments. As GDA-201 progresses through Phase I/II studies, positive clinical data could validate Gamida Cell's NK cell platform and attract strategic partnerships or further investment. The successful development and eventual commercialization of GDA-201 could position the company in the competitive but lucrative immunotherapy market within a 5-7 year horizon.
• Development of Broader NK Cell Pipeline: Gamida Cell's natural killer cell pipeline, including GDA-301, GDA-401, GDA-501, and GDA-601, targets a range of hematologic malignancies and solid tumors. This robust pipeline strategy allows the company to explore multiple therapeutic avenues and potentially develop a portfolio of NK cell-based immunotherapies. Each candidate represents an independent opportunity to address unmet needs in specific cancer types. Successful preclinical and early clinical development of these assets could significantly expand Gamida Cell's long-term market potential and intellectual property portfolio, positioning it for sustained growth beyond the next five years as these programs mature.
• Strategic Partnerships and Licensing Opportunities: Given its clinical-stage status and specialized cell therapy platforms, Gamida Cell has the opportunity to engage in strategic partnerships, collaborations, or licensing agreements with larger pharmaceutical companies. Such alliances could provide non-dilutive funding, leverage broader commercialization capabilities, and accelerate the development and market penetration of its pipeline candidates. For instance, a partnership for omidubicel's commercialization or for the co-development of NK cell therapies could significantly enhance Gamida Cell's financial stability and market reach, potentially within the next 1-2 years as its lead assets approach market readiness or show promising early-stage data.

What Opportunities Does GMDA Have?

• Potential regulatory approval and commercialization of omidubicel for hematologic malignancies.
• Expansion of omidubicel's indications to include severe aplastic anemia.
• Advancement and potential partnerships for the GDA-201 and broader NK cell pipeline.
• Growth in the overall cell therapy and cancer immunotherapy markets.

What Threats Does GMDA Face?

• Clinical trial failures, delays, or unexpected safety concerns for any pipeline candidate.
• Intense competition from other biotechnology and pharmaceutical companies developing similar therapies.
• Challenges in securing adequate funding for ongoing research and development.
• Adverse regulatory decisions or prolonged approval processes.

What Are GMDA's Competitive Advantages?

• Proprietary Cell Expansion Technologies: Specialized platforms for ex vivo expansion and engineering of cells, particularly for omidubicel and NK cell therapies, which are difficult to replicate.
• Advanced Clinical Pipeline: Lead product candidate, omidubicel, has completed Phase III trials, representing a significant lead time and data advantage over potential new entrants in specific indications.
• Intellectual Property: Patents and trade secrets protecting its cell therapy compositions, manufacturing processes, and methods of use.
• Specialized Expertise: Deep scientific and clinical expertise in cellular biology, oncology, and hematology, crucial for navigating complex R&D and regulatory pathways.

What Does GMDA Do?

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies aimed at curing blood cancers and other serious hematologic diseases. The company's foundational vision was to harness the power of cellular biology to address significant unmet medical needs in oncology and hematology. Over its history, Gamida Cell has evolved into a specialist in ex vivo cell expansion and engineering, focusing on creating therapies that can potentially offer curative options where standard treatments fall short. The company's lead product candidate is omidubicel, an advanced cell therapy designed to improve outcomes for patients undergoing bone marrow transplantation. Omidubicel has successfully completed Phase III clinical trials in patients suffering from high-risk hematologic malignancies, demonstrating its potential in a critical area of unmet need. Beyond this advanced stage, omidubicel is also being evaluated in Phase I/II clinical trials for the treatment of severe aplastic anemia, showcasing its versatility and potential applicability across different hematologic conditions. In addition to omidubicel, Gamida Cell is actively developing GDA-201, a natural killer (NK) cell-based cancer immunotherapy. GDA-201 is currently in Phase I/II studies, targeting challenging indications such as relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. This NK cell platform represents a significant strategic direction for the company, aiming to leverage the innate immune system's power to combat cancer. The broader NK cell pipeline further includes preclinical and early-stage candidates such as GDA-301, GDA-401, GDA-501, and GDA-601, which are being developed to address a wider spectrum of hematologic malignancies and solid tumors. With 143 employees, Gamida Cell maintains a focused approach on its research and development initiatives, aiming to bring these potentially life-saving therapies to patients globally.

What Products and Services Does GMDA Offer?

• Develops cell therapies to treat blood cancers and serious hematologic diseases.
• Focuses on clinical-stage biopharmaceutical research and development.
• Advances omidubicel, a lead cell therapy candidate, through Phase III trials for high-risk hematologic malignancies.
• Investigates omidubicel in Phase I/II clinical trials for severe aplastic anemia.
• Develops GDA-201, a natural killer (NK) cell-based cancer immunotherapy, in Phase I/II studies.
• Targets relapsed or refractory non-Hodgkin lymphoma and multiple myeloma with GDA-201.
• Maintains a broader NK cell pipeline (GDA-301, GDA-401, GDA-501, GDA-601) for various cancers.
• Aims to provide curative options using advanced cellular biology.

How Does GMDA Make Money?

• Primarily focused on research and development (R&D) of novel cell therapies.
• Future revenue generation is anticipated from the commercialization of approved cell therapy products.
• Potential for licensing agreements or strategic partnerships for product development and market access.
• Currently operates as a clinical-stage company, investing heavily in trials and pipeline advancement.
• Relies on external funding, such as equity financing or grants, to support R&D activities.

What Industry Does GMDA Operate In?

Gamida Cell Ltd. operates within the highly innovative and rapidly expanding biotechnology sector, specifically focusing on cell therapies for blood cancers and serious hematologic diseases. This segment of the healthcare industry is characterized by significant research and development investments, long development cycles, and substantial regulatory hurdles, yet it holds immense potential for transformative treatments. The broader cell therapy market is experiencing robust growth, driven by advancements in scientific understanding, technological innovation in cell engineering, and increasing demand for more effective treatments for conditions with high unmet needs. Gamida Cell's positioning with its lead candidate, omidubicel, having completed Phase III trials, places it among a select group of companies nearing potential commercialization in the highly competitive bone marrow transplant and hematologic malignancy space. The company's natural killer (NK) cell pipeline further diversifies its approach, tapping into the burgeoning field of cancer immunotherapies, where competition from both established pharmaceutical giants and numerous emerging biotechs is intense. Success in this industry hinges on demonstrating superior clinical outcomes, securing intellectual property, and navigating complex regulatory pathways.

Who Are GMDA's Key Customers?

• Patients suffering from blood cancers, including high-risk hematologic malignancies, non-Hodgkin lymphoma, and multiple myeloma.
• Patients with serious hematologic diseases, such as severe aplastic anemia.
• Healthcare providers, including oncologists, hematologists, and transplant centers, who administer these specialized therapies.
• Potentially, other pharmaceutical companies seeking to license or partner on advanced cell therapy technologies.

FY2026 estForward Outlook

Wall Street analysts project Gamida Cell Ltd. revenue of about $371.4M for fiscal 2026, with EPS near $0.90.

Key Financial Metrics

Return on assets is -61.6%, showing how much profit it generates from its asset base. A current ratio of 2.16 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 2/9Financial Health

Gamida Cell Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.90 places it in the distress zone, a signal of elevated financial risk.

GMDA Valuation & Market Position

With a $4.34M market cap, Gamida Cell Ltd. sits in the micro-cap segment of the market. Relative to its peer group, GMDA's quantitative score of 49/100 is below the peer average of 76/100.

GMDA Financials

GMDA Latest News

No recent news available for GMDA.

GMDA Analyst Consensus

GMDA MoonshotScore

Gamida Cell Ltd. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources